Loading
A phase 1/2 trial of sacituzumab tirumotecan and anlotinib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT07139470 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 59 participants, started 2025-08-15 and due to reach its primary completion in 2027-04-15. Interventions recorded: Sacituzumab Tirumotecan + anlotinib. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or pathological specimen, including:". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Anlotinib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.